Instrument Utility for Suspected Asthma (0000-042)(COMPLETED)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00211575
First received: September 13, 2005
Last updated: November 11, 2013
Last verified: November 2013

September 13, 2005
November 11, 2013
May 2003
December 2004   (final data collection date for primary outcome measure)
Utility of ARQ as measured by the percentage of children started on any asthma medication and characteristics of those diagnosed with asthma
Same as current
Complete list of historical versions of study NCT00211575 on ClinicalTrials.gov Archive Site
Percentage of children with recurrent wheezing, placed on controller therapy, number of steroid courses and need for urgent medical care at 6 and 12 months
Same as current
Not Provided
Not Provided
 
Instrument Utility for Suspected Asthma (0000-042)(COMPLETED)
Clinical Utility of an Instrument in the Evaluation of Young Children With Suspected Asthma

This research study was designed to help improve the diagnosis and treatment of asthma in young children. An interventional strategy using a scoring system based on risk factors and symptoms/episodes was tested to determine its ability to identify children likely to benefit from induction of asthma controller therapy at an early age. The score was derived through completion of a survey instrument referred to as the asthma risk questionnaire (ARQ). The utility of the ARQ along with the health care utilization and use of controller therapy for respiratory illnesses within one year were examined.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Asthma
Behavioral: Disease Management Assessment
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
400
December 2004
December 2004   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Children less than or equal to 6 years of age who had at least 1 year prior episode of wheezing

Exclusion Criteria:

  • Children with other systemic or chronic respiratory disease and children who used an asthma controller medication with the 6 weeks prior to enrollment
Both
up to 6 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00211575
0000-042, 042, 2005_073
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
November 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP